Literature DB >> 8452572

Criteria for the identification of non-redox inhibitors of 5-lipoxygenase.

J P Falgueyret1, J H Hutchinson, D Riendeau.   

Abstract

Methoxyalkyl thiazoles have been identified as a novel series of selective 5-lipoxygenase inhibitors with anti-inflammatory properties (Bird et al., J Med Chem 34: 2176-2186, 1991). Based on their structure, it was proposed that the potency of these compounds is not due to redox or iron-chelating properties. In the studies reported here, it was found that the model compounds 1-[3-(naphth-2-ylmethoxy)phenyl]-1-(thiazol-2-yl)propy l methyl ether (ICI 211965) and 3-[1-(4-chlorobenzyl)-4-methyl-6-(5- phenylpyridin-2-ylmethoxy)-4,5-dihydro-1H-thiopyrano[2 ,3,4-c,d]indol-2- yl]-2,2-dimethylpropanoic acid (L-689,065) (1) are inactive as reducing substrates in the 5-lipoxygenase-catalyzed decomposition of lipid hydroperoxides, (2) inhibit the 5-lipoxygenase-catalyzed reaction of reducing agents with lipid hydroperoxides, and (3) strongly inhibit the turnover-dependent inactivation of 5-lipoxygenase. These three observations with ICI 211965 and L-689,065 are in contrast to the behavior of other potent 5-lipoxygenase inhibitors from other structural classes, such as L-670,630, BW A4C, and zileuton, which all function as reducing substrates for 5-lipoxygenase. The data indicate that methoxyalkyl thiazoles and thiopyranoindoles are reversible dead-end inhibitors of 5-lipoxygenase and that the effects of inhibitors on the pseudoperoxidase activity and rate of enzyme inactivation provide simple tests to distinguish between redox and non-redox inhibitors of 5-lipoxygenase.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452572     DOI: 10.1016/0006-2952(93)90185-y

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  6 in total

1.  Pseudoperoxidase investigations of hydroperoxides and inhibitors with human lipoxygenases.

Authors:  Eric K Hoobler; Charles Holz; Theodore R Holman
Journal:  Bioorg Med Chem       Date:  2013-04-18       Impact factor: 3.641

2.  Structure-activity relationship studies of flavonoids as potent inhibitors of human platelet 12-hLO, reticulocyte 15-hLO-1, and prostate epithelial 15-hLO-2.

Authors:  Yesseny Vasquez-Martinez; Rachana V Ohri; Victor Kenyon; Theodore R Holman; Silvia Sepúlveda-Boza
Journal:  Bioorg Med Chem       Date:  2007-08-22       Impact factor: 3.641

3.  Discovery of a novel dual fungal CYP51/human 5-lipoxygenase inhibitor: implications for anti-fungal therapy.

Authors:  Eric K Hoobler; Ganesha Rai; Andrew G S Warrilow; Steven C Perry; Christopher J Smyrniotis; Ajit Jadhav; Anton Simeonov; Josie E Parker; Diane E Kelly; David J Maloney; S L Kelly; Theodore R Holman
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

4.  Regulation of leukotriene and 5oxoETE synthesis and the effect of 5-lipoxygenase inhibitors: a mathematical modeling approach.

Authors:  Tatiana A Karelina; Kirill V Zhudenkov; Oleg O Demin; Dmitry V Svetlichny; Balaji Agoram; David Fairman; Oleg V Demin
Journal:  BMC Syst Biol       Date:  2012-11-12

5.  A fluorescence-based assay for measuring the redox potential of 5-lipoxygenase inhibitors.

Authors:  Sangchul Lee; Youngsam Park; Junghwan Kim; Sung-Jun Han
Journal:  PLoS One       Date:  2014-02-03       Impact factor: 3.240

6.  Inflammation, Cancer and Oxidative Lipoxygenase Activity are Intimately Linked.

Authors:  Rosalina Wisastra; Frank J Dekker
Journal:  Cancers (Basel)       Date:  2014-07-17       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.